Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 148

Sort by

Sort Order Select

Journal Articles

Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 152.

https://doi.org/10.1182/blood-2025-152

Published: 2025

Journal Articles

EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort

Blood (2025) 146 (Supplement 1): 52.

https://doi.org/10.1182/blood-2025-52

Published: 2025

Journal Articles

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

Meng Wang, Joji Shimono, Shashwat Sahay, Chidimma Agatha Akpa, Christina Schniederjohann, Julia Richter, Peter-Martin Bruch, Ulrich Dührsen, Michael Hummel, Andreas Rosenwald, Wolfram Klapper, Sascha Dietrich, Ulrich Keller, Björn Chapuy

Blood (2025) 146 (Supplement 1): 50.

https://doi.org/10.1182/blood-2025-50

Published: 2025

Journal Articles

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab

Johannes Duell, Diana Alvarez Arias, Wolfram Klapper, Sarah Reinke, Florian Eisele, Thomas Larsen, Prof. Dr. Max S Topp, Beth Rumberger, TaeHyung (Simon) Kim, Andreas Rosenwald, Hilka Rauert-Wunderlich

Blood (2025) 146 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2025-5515

Published: 2025

Journal Articles

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma

Hishan Tharmaseelan, Sarah Gillessen, Ina Bühnen, Carsten Kobe, Karin G. Schrenk, Prof. Dr. Max S Topp, Ulf Schnetzke, Nico Freund, Stephanie Sasse, Philipp Ernst, Tanja Zamrik, Wolfram Klapper, Michael Fuchs, Sven Borchmann, Paul Bröckelmann, Peter Borchmann, Bastian von Tresckow

Blood (2025) 146 (Supplement 1): 5401.

https://doi.org/10.1182/blood-2025-5401

Published: 2025

Journal Articles

Integrated clinico-biological profiling identifies a high-risk epigenetic signature in Mantle Cell Lymphoma: A lysa study

Blood (2025) 146 (Supplement 1): 661.

https://doi.org/10.1182/blood-2025-661

Published: 2025

Journal Articles

High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition

Blood blood.2025031086.

https://doi.org/10.1182/blood.2025031086

Published: 2025

Includes: Supplemental data

Journal Articles

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

Adrian Gottschlich, Ruth Grünmeier, Gordon Victor Hoffmann, Sayantan Nandi, Vladyslav Kavaka, Philipp Jie Müller, Jakob Jobst, Arman Oner, Rainer Kaiser, Jan Gärtig, Ignazio Piseddu, Stephanie Frenz-Wiessner, Savannah D. Fairley, Heiko Schulz, Veronika Igl, Thomas Alexander Janert, Lea Di Fina, Maité Mulkers, Moritz Thomas, Daria Briukhovetska, Donjetë Simnica, Emanuele Carlini, Christina Angeliki Tsiverioti, Marcel P. Trefny, Theo Lorenzini, Florian Märkl, Pedro Mesquita, Ruben Brabenec, Thaddäus Strzalkowski, Sophia Stock, Stefanos Michaelides, Johannes Hellmuth, Martin Thelen, Sarah Reinke, Wolfram Klapper, Pascal Francois Gelebart, Leo Nicolai, Carsten Marr, Eduardo Beltrán, Remco T. A. Megens, Christoph Klein, Fanny Baran-Marszak, Andreas Rosenwald, Michael von Bergwelt-Baildon, Paul J. Bröckelmann, Stefan Endres, Sebastian Kobold

Blood (2025) 145 (14): 1536–1552.

https://doi.org/10.1182/blood.2023022197

Published: 2025

Includes: Supplemental data

Journal Articles

Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure

Tim Versteegen, Philipp Nakov, Nikos Darzentas, Guranda Chitadze, Ingram Iaccarino, Wolfram Klapper, Natalie Schub, Monika Brüggemann, Friedrich Stoelzel, Claudia D Baldus, Christiane Pott, Mouhamad Khouja

Blood (2024) 144 (Supplement 1): 2959.

https://doi.org/10.1182/blood-2024-207721

Published: 2024

Journal Articles

Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4796.

https://doi.org/10.1182/blood-2024-207274

Published: 2024

Journal Articles

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 230.

https://doi.org/10.1182/blood-2024-209616

Published: 2024

Journal Articles

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2024) 144 (Supplement 1): 240.

https://doi.org/10.1182/blood-2024-200735

Published: 2024

Journal Articles

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Blood (2024) 144 (Supplement 1): 237.

https://doi.org/10.1182/blood-2024-201441

Published: 2024

Journal Articles

SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features

Blood (2024) 144 (2): 187–200.

https://doi.org/10.1182/blood.2023023242

Published: 2024

Includes: Supplemental data

Journal Articles

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

Blood (2024) 144 (1): 74–83.

https://doi.org/10.1182/blood.2024023938

Published: 2024

Includes: Supplemental data

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6935.

https://doi.org/10.1182/blood-2023-189047

Published: 2023

Journal Articles

Contrasting Features of T-Cell Expansion in Classical Hodgkin Lymphoma: Tumor Microenvironment Vs. Peripheral Blood and before Vs. during Anti-PD1 Treatment

Nicole Seifert, Sarah Reinke, Johanna Grund, Berit Müller-Meinhard, Andreas Engert, Peter Borchmann, Paul J Bröckelmann, Michael Altenbuchinger, Wolfram Klapper

Blood (2023) 142 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2023-186527

Published: 2023

Journal Articles

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Blood (2023) 142 (Supplement 1): 71.

https://doi.org/10.1182/blood-2023-178815

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma

EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma

Integrated clinico-biological profiling identifies a high-risk epigenetic signature in Mantle Cell Lymphoma: A lysa study

High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure

Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

SOX11 expression is restricted to EBV-negative Burkitt lymphoma and is associated with molecular genetic features

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

Contrasting Features of T-Cell Expansion in Classical Hodgkin Lymphoma: Tumor Microenvironment Vs. Peripheral Blood and before Vs. during Anti-PD1 Treatment

Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration

Genomic profiling for clinical decision making in lymphoid neoplasms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only